2016 American Transplant Congress
Novel Approaches to Medication Teaching in Solid Organ Transplantation.
NewYork-Presbyterian Hospital, Columbia University, New York.
Technology has become a fundamental part of our daily lives; mobile application (app) technologies enhance a healthcare providers ability to deliver patient-centered care. Solid organ…2016 American Transplant Congress
The Medication Level Variability Index (MLVI), a Behavioral Biomarker, Predicts Late Allograft Rejection in Pediatric Liver Transplant Recipients – A Prospective Multisite Study.
Objective: The MALT [Medication Adherence in children who had a Liver Transplant (LT), NCT-01154075, R01DK080740 (NIDDK)] multisite study prospectively evaluated a biomarker for erratic medication…2016 American Transplant Congress
NAD+ Promotes Allograft Survival Independently of CD4+CD25+Foxp3+ Regulatory T Cells.
CD4+CD25+Foxp3+ regulatory T cells (Tregs) play a central role in the maintenance of immune tolerance and T cell homeostasis. It is known that Tregs promote…2016 American Transplant Congress
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.
Controversy exists regarding the optimal choice of induction therapy in low-risk kidney transplant (KT) recipients. Current guidelines specify induction choices in KT based on recipient…2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
1Emory Transplant Center, Atlanta, GA; 2Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…2016 American Transplant Congress
The Impact of Different Immunosuppressive Protocols on Early and Long Term Outcomes After Kidney and Pancreas Transplantation.
Surgery/Transplant, The Ohio State University Wexner Medical Center, Columbus, OH.
Between January 1990 and December 2014, 800 combined kidney pancreas transplant procedures were performed at The Ohio State University. The immunosuppressive protocols have changed significantly…2016 American Transplant Congress
Appraisal of Alternative Immunosuppression Regimens in Intestinal Transplant Recipients: A Single Center Experience.
Purpose: The purpose of this study was to compare outcomes (acute cellular rejection, graft loss, mortality) in intestinal transplant recipients who were converted from the…2016 American Transplant Congress
High Tacrolimus Dose Requirements at Month 6 Are Associated with Inferior Graft Function in Renal Transplant Patients.
Department of Nephrology, Charité Universitaetsmedizin, Berlin, Germany.
Introduction: Tacrolimus (Tac), the mainstay of immunosuppression in renal transplant (tx) patients (pts) is known for drug induced nephrotoxicity, which may limit graft survival.Methods: In…2016 American Transplant Congress
Steroid Use May Not Increase Risk of Fracture in Kidney Transplant Patients.
Introduction: Chronic steroid use is associated with bone mineral loss, and osteoporosis. However, it is not clear if chronic steroid use in post-kidney transplant patients…2016 American Transplant Congress
Tumor-Necrosis-Factor-α Antagonist Therapy for Inflammatory Bowel Disease After Liver Transplantation.
Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI.
Background:The safety and effectiveness of tumor-necrosis-factor-α antagonist (anti-TNF-α) therapy for inflammatory bowel disease (IBD) has not been well-established in patients after liver transplantation (LT). We…
- « Previous Page
- 1
- …
- 106
- 107
- 108
- 109
- 110
- …
- 138
- Next Page »